Novartis Ag (NVSEF) EBITDA Margin (2009 - 2025)

Novartis Ag has disclosed EBITDA Margin across 15 years of filings, most recently posting 34.61% for Q2 2025.

• EBITDA Margin for Q2 2025 came in at 34.61%, up 253.0% year-over-year; the trailing twelve-month figure through Jun 2025 was 29.65% (up 264.0% YoY), and the FY2025 annual result was 32.36%, up 345.0% from the prior year.
• EBITDA Margin came in at 34.61% for Q2 2025 at Novartis Ag, up from 30.35% in the prior quarter.
• In the past five years, EBITDA Margin ranged from a high of 194.69% in Q3 2021 to a low of 1.52% in Q4 2021.
• The 5-year median for EBITDA Margin is 33.35% (2025), against an average of 72.61%.
• Peak annual rise in EBITDA Margin reached 12986 bps in 2021, while the deepest fall reached 15220 bps in 2021.
• Novartis Ag's EBITDA Margin stood at 1.52% in 2021, then surged by 6963 bps to 107.48% in 2022, then slumped by 77 bps to 24.4% in 2023, then gained by 24 bps to 30.35% in 2024, then advanced by 14 bps to 34.61% in 2025.
• The last three EBITDA Margin figures came in at 34.61% (Q2 2025), 30.35% (Q4 2024), and 32.08% (Q2 2024), per Business Quant data.